Cargando…
Comparing BMD‐derived genotoxic potency estimations across variants of the transgenic rodent gene mutation assay
There is growing interest in quantitative analysis of in vivo genetic toxicity dose‐response data, and use of point‐of‐departure (PoD) metrics such as the benchmark dose (BMD) for human health risk assessment (HHRA). Currently, multiple transgenic rodent (TGR) assay variants, employing different rod...
Autores principales: | Wills, John W., Johnson, George E., Battaion, Hannah L., Slob, Wout, White, Paul A., Gollapudi, B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698699/ https://www.ncbi.nlm.nih.gov/pubmed/28945287 http://dx.doi.org/10.1002/em.22137 |
Ejemplares similares
-
Empirical comparison of genotoxic potency estimations: the in vitro DNA-damage ToxTracker endpoints versus the in vivo micronucleus assay
por: Wills, John W, et al.
Publicado: (2021) -
The impact of obesity on the accuracy of DXA BMD for DXA-equivalent BMD estimation
por: Kim, Min-Woo, et al.
Publicado: (2022) -
bmd: an R package for benchmark dose estimation
por: Jensen, Signe M., et al.
Publicado: (2020) -
Effect of physicochemical character differences on the genotoxic potency of kaolin
por: Kato, Tatsuya, et al.
Publicado: (2017) -
Summary of carcinogenic potency and positivity for 492 rodent carcinogens in the carcinogenic potency database.
por: Gold, L S, et al.
Publicado: (1989)